Literature DB >> 12695531

Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors.

Tamas Virag1, Don B Elrod, Karoly Liliom, Vineet M Sardar, Abby L Parrill, Kazuaki Yokoyama, Gangadhar Durgam, Wenlin Deng, Duane D Miller, Gabor Tigyi.   

Abstract

A more complete understanding of the physiological and pathological role of lysophosphatidic acid (LPA) requires receptor subtype-specific agonists and antagonists. Here, we report the synthesis and pharmacological characterization of fatty alcohol phosphates (FAP) containing saturated hydrocarbon chains from 4 to 22 carbons in length. Selection of FAP as the lead structure was based on computational modeling as a minimal structure that satisfies the two-point pharmacophore developed earlier for the interaction of LPA with its receptors. Decyl and dodecyl FAPs (FAP-10 and FAP-12) were specific agonists of LPA(2) (EC(50) = 3.7 +/- 0.2 microM and 700 +/- 22 nM, respectively), yet selective antagonists of LPA(3) (K(i) = 90 nM for FAP-12) and FAP-12 was a weak antagonist of LPA(1). Neither LPA(1) nor LPA(3) receptors were activated by FAPs; in contrast, LPA(2) was activated by FAPs with carbon chains between 10 and 14. Computational modeling was used to evaluate the interaction between individual FAPs (8 to 18) with LPA(2) by docking each compound in the LPA binding site. FAP-12 displayed the lowest docked energy, consistent with its lower observed EC(50). The inhibitory effect of FAP showed a strong hydrocarbon chain length dependence with C12 being optimum in the Xenopus laevis oocytes and in LPA(3)-expressing RH7777 cells. FAP-12 did not activate or interfere with several other G-protein-coupled receptors, including S1P-induced responses through S1P(1,2,3,5) receptors. These data suggest that FAPs are ligands of LPA receptors and that FAP-10 and FAP-12 are the first receptor subtype-specific agonists for LPA(2).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695531     DOI: 10.1124/mol.63.5.1032

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  29 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

3.  2D binary QSAR modeling of LPA3 receptor antagonism.

Authors:  James I Fells; Ryoko Tsukahara; Jianxiong Liu; Gabor Tigyi; Abby L Parrill
Journal:  J Mol Graph Model       Date:  2010-03-07       Impact factor: 2.518

4.  Identification of non-lipid LPA3 antagonists by virtual screening.

Authors:  James I Fells; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; Donna H Perygin; Daniel A Osborne; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Self-assembly of phosphate amphiphiles in mixtures of prebiotically plausible surfactants.

Authors:  A N Albertsen; C D Duffy; J D Sutherland; P-A Monnard
Journal:  Astrobiology       Date:  2014-06-02       Impact factor: 4.335

7.  Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.

Authors:  Daniel L Baker; Yuko Fujiwara; Kathryn R Pigg; Ryoko Tsukahara; Susumu Kobayashi; Hiromu Murofushi; Ayako Uchiyama; Kimiko Murakami-Murofushi; Eunjin Koh; Russell W Bandle; Hoe-Sup Byun; Robert Bittman; Dominic Fan; Mandi Murph; Gordon B Mills; Gabor Tigyi
Journal:  J Biol Chem       Date:  2006-06-16       Impact factor: 5.157

Review 8.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

Review 9.  Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.

Authors:  Glenn D Prestwich; Joanna Gajewiak; Honglu Zhang; Xiaoyu Xu; Guanghui Yang; Monica Serban
Journal:  Biochim Biophys Acta       Date:  2008-04-08

10.  The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury.

Authors:  Wenlin Deng; E Shuyu; Ryoko Tsukahara; William J Valentine; Gangadhar Durgam; Veeresa Gududuru; Louisa Balazs; Venkatraman Manickam; Marcello Arsura; Lester VanMiddlesworth; Leonard R Johnson; Abby L Parrill; Duane D Miller; Gabor Tigyi
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.